



# OxySure Systems, Inc. (OXYS)

Stockholder Update Conference Call

February 4, 2014

It's About Time.

# Forward Looking Statements

The following may contain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this communication, including statements relating to our growth strategy, financial results, product approvals, and development programs, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance to differ materially from the forward-looking statements we make include: range of treatment options, clinical applications, and market acceptance of products and other risks detailed from time to time in our filings with the Securities and Exchange Commission. Our actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors.



# Agenda

- Review of prior results
- Status of 10K for FY2013
- Goals for 2014
- Q&A

## 3Q 2013 Financial Results

- Total revenue increased by approximately 428% to \$545,820
- Interest expense down by approximately 15% to \$47,180
- Working capital deficit improved by approximately \$2,204,966
- Stockholder deficit improved by approximately \$2,080,000
- Gross profit increased approximately 722% to \$434,710
- Net loss down by approximately 38.3% to \$82,613 or \$0.00 per share




# 3Q 2013 Financial Results

- Aggressive growth, while managing expenses
- Realizing benefits of prior and current:
  - Research and development
  - Sales and marketing initiatives
- Sustained positive year to date momentum
  - Significant repeat business
  - Expanded distribution
  - License and service revenues
  - Sales of products for Military
- Third Consecutive Quarter of Triple Digit Revenue Growth




# 3Q 2013 Financial Results

Q/Q Results – 3Q13 v 3Q12 (in thousands)




# 3Q 2013 Financial Results

Sequential Quarterly Results (in thousands)



# 3Q 2013 Financial Results

Q/Q Results (in thousands)





# 3Q 2013 Financial Results

<b>3Q 2013 3 Months</b>	<b>3Q 2012 3 Months</b>
<b>Revenues:</b>	
<b>\$545,820</b>	<b>\$103,327</b>
<b>Net income (loss):</b>	
<b>\$(82,613)</b>	<b>\$(133,779)</b>
<b>Net income (loss) per share:</b>	
<b>\$(.00)</b>	<b>\$(.01)</b>



# 3Q 2013 Financial Results

<b>3Q 2013 9 Months</b>	<b>3Q 2012 9 Months</b>
<b>Revenues:</b>	
<b>\$1,262,311</b>	<b>\$194,102</b>
<b>Net income (loss):</b>	
<b>\$(444,571)</b>	<b>\$(678,001)</b>
<b>Net income (loss) per share:</b>	
<b>\$(.02)</b>	<b>\$(.03)</b>



# Key Milestones and Announcements

- OUS distribution: Chile, Hong Kong and Macau
- \$750,000 Series B Institutional Financing
- Standard & Poor's research coverage; Market Access
- Improved Balance Sheet by Reducing Debt by Nearly \$1 Million



# Update on Status of 10K

- Audit field work mid-February
- Target early to mid-March for filing



# Goals for 2014

- Grow revenue aggressively
- Add new distribution partners in US
- Add new distribution partners outside the US
- Pursue new regulatory approvals



# Goals for 2014

- Marketing and Branding
- Product enhancements
- Launch new products
- Achieve additional operational efficiencies
- Pursue strategic alliances



# Growth Summary, 3-5 Years

## Grow Placement Markets

- Grow distributors; US + ROW
- Grow strategic accounts teams
- Pursue legislation / mandates
- Aggressively pursue 3 million+ unit 'AED companion' market, and 100 million+ unit general placement markets

## Grow At Risk Markets

- Pursue insurance reimbursement (Medicare, private)
- Execute rolling short/long form commercial campaign(s) targeting 100 million+ US and 500 million+ ROW 'at risk' customers

## New Vertical Mass Markets

- Military
- Mining
- Aviation
- Sports/Recreation
- Skin care
- Wound care
- Automotive

**+ Strategic Alliances**



# Stockholder update call

OxySure Systems, Inc. (OXYS)

[info@oxysure.com](mailto:info@oxysure.com)

[www.oxysure.com](http://www.oxysure.com)

Questions & Answers





# Contact Information

OxySure Systems, Inc.

**OXYS: OTCQB**

10880 John W. Elliott Road, Suite 600

Frisco, TX 75034 USA

Tel: (+1) 972-294-6461

[info@oxysure.com](mailto:info@oxysure.com)

[www.OxySure.com](http://www.OxySure.com)



Barwicki Investor Relations

Andrew Barwicki

Tel: +1-516-662-9461

Email: [andrew@barwicki.com](mailto:andrew@barwicki.com)

Maximum Performance Advisors, Inc.

Christian Hansen

Tel: +1-(858) 381-4677

Email: [christian@maximumperformanceadvisors.com](mailto:christian@maximumperformanceadvisors.com)

